NeuroBo Pharmaceuticals, Inc.
NASDAQ:NRBO
2.36 (USD) • At close November 27, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.007 | 0.028 | 0.072 | 0.067 | 0.017 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | -0.028 | -0.072 | -0.067 | -0.017 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 21.553 | 9.151 | 2.778 | 6.546 | 21.87 | 17.475 | 14.312 | 22.686 | 8.74 | 3.991 | 0.052 |
| General & Administrative Expenses
| 7.256 | 6.728 | 8.64 | 8.752 | 7.846 | 2.701 | 8.493 | 0.06 | 5.956 | 3.177 | 0.214 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.378 | 0 | 0 | 0 |
| SG&A
| 7.256 | 6.728 | 8.64 | 8.752 | 7.846 | 2.701 | 8.493 | 10.438 | 5.956 | 3.177 | 0.214 |
| Other Expenses
| 0 | 0 | -0.083 | 0 | -0.001 | 12.151 | -0.178 | 10.438 | 0 | 0 | 0 |
| Operating Expenses
| 28.809 | 15.879 | 11.418 | 15.298 | 29.716 | 20.176 | 22.805 | 33.124 | 14.696 | 7.168 | 0.266 |
| Operating Income
| -28.809 | -15.886 | -19.628 | -15.298 | -29.716 | -20.176 | -22.805 | -33.124 | -14.696 | -8.076 | -0.266 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.217 | 3.416 | 5.661 | 0.014 | 0.038 | -1.136 | -0.043 | -0.291 | 0.11 | -0.953 | -0.054 |
| Income Before Tax
| -27.592 | -12.47 | -13.967 | -15.284 | -29.678 | -21.312 | -23.637 | -33.415 | -14.586 | -9.029 | -0.32 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -7.852 | -0.062 | -0.085 | 1.119 | 0.654 | 0.286 | -0.137 | -0.146 | 0.055 |
| Net Income
| -27.592 | -12.47 | -6.115 | -15.222 | -29.593 | -22.431 | -23.637 | -33.415 | -14.586 | -9.029 | -0.32 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -3.56 | -2.46 | -19.01 | -157.85 | -437.95 | -1,030.5 | -166.8 | -2,421.73 | -1,883.28 | -1,277.45 | -45.27 |
| EPS Diluted
| -3.56 | -2.46 | -19.01 | -157.85 | -437.95 | -1,030.5 | -166.8 | -2,421.73 | -1,883.28 | -1,277.45 | -45.27 |
| EBITDA
| -28.809 | -12.463 | -11.398 | -15.212 | -29.611 | -21.166 | -15.488 | -33.087 | -14.5 | -6.069 | -0.283 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |